UMC Utrecht Clinical Trials
Sponsors / UMC Utrecht
ClinicalTrials.gov lists 186 trials for which UMC Utrecht is named as lead sponsor. The portfolio currently includes 20 recruiting studies, 2 active non-recruiting studies, and 91 completed studies. 20 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include slow or insufficient recruitment, efficacy or futility findings. Cumulative planned enrollment across all listed trials is 1,377,926 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.
186
Total Trials
20
Recruiting
2
Other Active
91
Completed
20
Terminated / Withdrawn
1,377,926
Total Enrollment
Termination reasons: Other50% · Recruitment35% · Efficacy10% · Funding5%
Recent Terminations
- Acute Otitis Media"Trial accrual problems"
- Angiotensin Hypertension"slow recruitment rate"
- NCT04462055 Stopped Jul 2022Food Allergy"Not feasible to include patients (due to e.g. COVID-19, patients with severe reactions not willing to undergo 2 food challenges, lower number of eligible patients than expected)"
- COVID-19"Currently, almost no patients admitted to Dutch hospitals. If any effect of HCQ is to be expected we need more than 1000 inclusions"
- Renal Cell Carcinoma"Slow inclusion"
- Psychotic Disorder NOS"Difficulties with recruitment"
- Arthritis, Rheumatoid"low recruitment rate"
- Head and Neck Neoplasms"Slow accrual"
- Uterine Fibroid
- NCT03489577 Stopped Jun 2016Disorder of Neutrophils"Interim analysis provided enough data"
Active Trials (2 total)
- NCT05992038
- NCT04861194
- Cancer PHASE1NCT06524570
- NCT07359417
- NCT06387693
- Fertility Issues PHASE4NCT05080569
- Digital Ulcer PHASE1/PHASE2NCT03211793
- NCT07146841
- NCT05078619
- NCT06480513
- NCT06650436
- NCT06124248
- Metastatic Colorectal Cancer PHASE2NCT06563986
- NCT06518226
- NCT04713605
- NCT02839863
- NCT05069792
- NCT06232889
- NCT04364334
- NCT05331118